| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50d00057d0793be0f315dc789a5ccdfb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33daceb58b620e740c23a3cbdf494278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_beb6367da1a08f3fe076872776a0901d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6ea5d20d2e96c3bfe7198345f2e9fc6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_330871624077650548f1b10227ee8fbc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4291
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-283 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2012-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47997cfe4b00d3c4739880cb54187f60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e8c824808867f9114d6843f59a4e6a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_deb26e4ffcd2e74b85048d2277cc68af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ae3c9a16dc2324425d8c04b207fe637
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31cded357be13a2ccbfee268dabe469e |
| publicationDate |
2014-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014314783-A1 |
| titleOfInvention |
Methods for suppressing allergic reactions |
| abstract |
Provided are methods for suppressing IgE and IgG-mediated allergic reactions through monoclonal antibody applications. More specifically, methods are herein provided for safe induction of rapid desensitization. Specific embodiments are herein provided for suppressing allergic reactions in a subject, including specific methods of providing a monoclonal antibody selected from the group consisting of anti-FcαRIa and anti-FcγRIIb/RIII; administering the antibody to a subject at a dose that is lower than the level required to induce shock; and administering sequentially escalating doses of the monoclonal antibody so as to induce rapid desensitization to an allergen, thereby suppressing allergic reaction in the subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112888482-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9795618-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10086005-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018179297-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10954307-B2 |
| priorityDate |
2011-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |